Harvard Bioscience
HBIO
HBIO
90 hedge funds and large institutions have $138M invested in Harvard Bioscience in 2024 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 27 increasing their positions, 41 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
22% less capital invested
Capital invested by funds: $177M → $138M (-$39.2M)
34% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 41
37% less call options, than puts
Call options by funds: $19K | Put options by funds: $30K
Holders
90
Holding in Top 10
2
Calls
$19K
Puts
$30K
Top Buyers
| 1 | +$684K | |
| 2 | +$219K | |
| 3 | +$210K | |
| 4 |
New York State Common Retirement Fund
Albany,
New York
|
+$152K |
| 5 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
+$112K |
Top Sellers
| 1 | -$618K | |
| 2 | -$590K | |
| 3 | -$442K | |
| 4 |
RA
Royce & Associates
New York
|
-$433K |
| 5 |
CIC
Cornercap Investment Counsel
Atlanta,
Georgia
|
-$418K |